We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Immatics

News List

Selexis, KBI Biopharma, Immatics Partner to Advance TCR Program contractpharma
July 01, 2021
Selexis SA and KBI Biopharma, both JSR Life Sciences companies, have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company focused on T cell redirecting cancer immunotherapies.
Immatics, Roche ally to trial Tecentriq with cell therapy fiercebiotech
February 27, 2019
Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors....
Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies b3cnewswire
July 24, 2018
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today that it has entered into a research collaboration and license agreement with Ge
Immatics, Genmab to develop bispecific cancer immunotherapies biospectrumasia
July 16, 2018
Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets